Pfizer to seek FDA approval for Lyme vaccine
Digest more
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer’s results,
Morning Overview on MSN
Pfizer, Valneva Lyme vaccine misses primary endpoint despite efficacy
Pfizer and Valneva’s experimental Lyme disease vaccine, VLA15, failed to meet the primary endpoint of its late-stage clinical trial, even though the shot demonstrated more than 70% efficacy against confirmed Lyme disease.
Tutanota offered $32 per Pfizer share for up to 1 million shares, expiring April 13, 2026, with plans to extend the bid until the stock exceeds $32. A closing-price condition could result in payment below prevailing market levels if unmet or waived,
Vaccine candidate PF-07307405 (LB6V) demonstrated more than 70% efficacy in preventing Lyme disease in individuals aged five years and above -- The investigational vaccine candidate was well tolerated with no safety concerns identified at time of analysis -- Overall,
As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas like Eli Lilly and Roche bolster their biotech offerings,
Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the in-licensing agreement with 3SBio, Inc. recorded in the third quarter of 2025 with an unfavorable impact of approximately $0.20. $7.2 billion invested in internal research and ...
Pfizer reported positive topline results in its phase three study of talazoparib in combination with enzalutamide to treat metastatic hormone-sensitive prostate cancer. The study met its primary endpoint,
Pfizer has reached a turning point.
Includes a one-time $1.35 billion Acquired In-Process R&D charge related to the licensing agreement with 3SBio, Inc. that will be recorded in the third quarter of 2025 with an expected unfavorable impact of approximately $0.20. $4.7 billion invested in ...
WASHINGTON, D.C. -- A major drug company is defending itself against accusations it kept promising and possibly life-saving data secret. The Washington Post reports that Pfizer decided against sharing findings that suggested one of its drugs, Enbrel, might ...